ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Two Studies Indicate Coblation(R) Safely Treats Symptomatic Chondral Defects In The Knee
Two new studies show
Coblation(R) devices were effective for safely treating symptomatic
chondral defects in the knee. The two studies were presented at the
Arthroscopic Association of North America (AANA) annual meeting held May 18
to 21 at the Westin Diplomat Resort & Spa, Hollywood, Florida.
Coblation is a patented technology (ArthroCare Corp. Nasdaq: ARTC) that
combines bipolar radiofrequency energy with a saline solution to gently and
precisely remove soft tissue at low temperatures, typically 40 to 70
degrees Celsius.
The first study, presented by Ferdinando Battistella, MD, orthopaedic
surgeon at Legano Hospital (Milan, Italy) is the first clinical study to
evaluate in vivo histologic findings after the use of bipolar
radiofrequency-based methods in articular cartilage of the knee. Results of
the study indicate this approach can be used to safely treat grades II and
III lesions in the knee.
"The cells in the tissue surrounding the treated area were healthy
months after the procedure, which may decrease the chance of long term
degeneration," said Battistella, lead author of the study titled: In Vivo
Histology Findings Through One Year After Clinical Use of Bipolar
Radiofrequency-Based Chondroplasty. "These findings are significant for
orthopaedic surgeons as I have also found Coblation is easy to use and
produces a smoother surface than a mechanical shaver during the debridement
of articular cartilage."
The study, conducted in Italy, included four patients awaiting total
knee replacement who were treated with arthroscopic chondroplasty using
Coblation. Second-look arthroscopy of treated defects in patients at six,
nine and 12 months following the procedure appeared viable and stable, with
no evidence of deterioration.
A second study, Osteonecrosis Following Arthroscopic Chondroplasty -- a
Retrospective Evaluation of 521 Patients Who Underwent Arthroscopic Knee
Surgery -- indicated no relationship between the onset of osteonecrosis and
the type of surgical device used for treating symptomatic chondral defects
in the knee. The study was presented by Dain Allred, MD, orthopaedic
surgeon at the University of Rochester School of Medicine.
Of the 521 patients receiving arthroscopic knee surgery and treatment
of chondral defects using Coblation alone, a mechanical shaver alone, or
both Coblation and a mechanical shaver, there were no cases of
osteonecrosis among the 52 people treated with Coblation alone. The rate of
osteonecrosis following chondroplasty with a mechanical shaver was 0.98
percent (2 out of 205 people), and among those who were treated using both
methods, the rate of osteonecrosis was 1.2 percent (3 out of 259 people).
For more information about bipolar radio frequency-based Coblation
Visit http://www.arthrocare.com.
ABOUT ARTHROCARE
Founded in 1993, ArthroCare Corp. ( http://www.arthrocare.com ) is a highly
innovative, multi-business medical device company that develops,
manufactures and markets minimally invasive surgical products. With these
products, ArthroCare targets a multi-billion dollar market opportunity
across several medical specialties, significantly improving existing
surgical procedures and enabling new, minimally invasive procedures. Many
of ArthroCare's products are based on its patented Coblation technology,
which uses low-temperature radiofrequency energy to gently and precisely
dissolve rather than burn soft tissue -- minimizing damage to healthy
tissue. Used in more than four million surgeries worldwide, Coblation-based
devices have been developed and marketed for sports medicine;
spine/neurologic; ear, nose and throat (ENT); cosmetic; urologic and
gynecologic procedures. ArthroCare also has added a number of novel
technologies to its portfolio, including Opus Medical sports medicine,
Parallax spine and Applied Therapeutics ENT products, to complement
Coblation within key indications.
SAFE HARBOR STATEMENTS
Except for historical information, this press release includes
forward-looking statements. These statements include, but are not limited
to, the company's stated business outlook for fiscal 2006 and 2007,
continued strength of the company's fundamental position, the strength of
the company's technology, the company's belief that strategic moves will
enhance achievement of the company's long term potential, the potential and
expected rate of growth of new businesses, continued success of product
diversification efforts, and other statements that involve risks and
uncertainties. These risks and uncertainties include, but are not limited
to the uncertainty of success of the company's non-arthroscopic products,
competitive risk, uncertainty of the success of strategic business
alliances, uncertainty over reimbursement, need for governmental clearances
or approvals before selling products, the uncertainty of protecting the
company's patent position, and any changes in financial results from
completion of year-end audit activities. These and other risks and
uncertainties are detailed from time to time in the company's Securities
and Exchange Commission filings, including ArthroCare's Form 10-Q for the
quarter ended Sept. 30, 2005 and Form 10-K for the year ended Dec. 31,
2005. Forward-looking statements are indicated by words or phrases such as
"anticipates," "estimates," "projects," "believes," "intends," "expects,"
and similar words and phrases. Actual results may differ materially from
management expectations.
ArthroCare Corp.
http://www.arthrocare.com
Douã studii Coblation (R) Safely trateazã simptomaticã Chondral defecte de genunchiul - Two Studies Indicate Coblation(R) Safely Treats Symptomatic Chondral Defects In The Knee - articole medicale engleza - startsanatate